ClearPoint Neuro (NASDAQ:CLPT) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.29) by 31.03 percent. This is a 80.95 percent decrease over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $10.880 million which missed the analyst consensus estimate of $12.733 million by 14.55 percent. This is a 18.07 percent increase over sales of $9.215 million the same period last year.